- Home
- PLRX vs INCR Comparison
PLRX vs INCR Comparison
Compare PLRX & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- INCR
- Stock Information
- Founded
- PLRX 2015
- INCR 1994
- Country
- PLRX United States
- INCR Israel
- Employees
- PLRX N/A
- INCR N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- INCR Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- INCR Health Care
- Exchange
- PLRX Nasdaq
- INCR Nasdaq
- Market Cap
- PLRX 84.7M
- INCR 83.9M
- IPO Year
- PLRX 2020
- INCR N/A
- Fundamental
- Price
- PLRX $1.28
- INCR $1.52
- Analyst Decision
- PLRX Hold
- INCR
- Analyst Count
- PLRX 10
- INCR 0
- Target Price
- PLRX $9.79
- INCR N/A
- AVG Volume (30 Days)
- PLRX 950.8K
- INCR 7.4K
- Earning Date
- PLRX 08-06-2025
- INCR 08-15-2025
- Dividend Yield
- PLRX N/A
- INCR N/A
- EPS Growth
- PLRX N/A
- INCR N/A
- EPS
- PLRX N/A
- INCR N/A
- Revenue
- PLRX N/A
- INCR $65,575,323.00
- Revenue This Year
- PLRX N/A
- INCR $69.54
- Revenue Next Year
- PLRX N/A
- INCR $41.75
- P/E Ratio
- PLRX N/A
- INCR N/A
- Revenue Growth
- PLRX N/A
- INCR N/A
- 52 Week Low
- PLRX $1.10
- INCR $1.17
- 52 Week High
- PLRX $16.10
- INCR $2.62
- Technical
- Relative Strength Index (RSI)
- PLRX 36.66
- INCR 50.58
- Support Level
- PLRX $1.56
- INCR $1.47
- Resistance Level
- PLRX $1.70
- INCR $1.54
- Average True Range (ATR)
- PLRX 0.12
- INCR 0.05
- MACD
- PLRX -0.02
- INCR -0.00
- Stochastic Oscillator
- PLRX 5.68
- INCR 50.00
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.